Navigation Links
Medivation Announces Presentation of Full Top-Line Data From,Dimebon Six-Month Trial at Major International Alzheimer's Disease,Conference

acebo consistently across all five endpoints studied, including both of the endpoints accepted by the FDA to register drugs for mild to moderate Alzheimer's disease. And second, Dimebon was well tolerated in this study, with less than three percent incidence of the gastrointestinal side effects that sometimes limit utilization of approved cholinesterase inhibitor drugs. Based on these data, I look forward to participating in the planned Phase 3 trials of this promising drug candidate."

The study of 183 patients was conducted at multiple sites in Russia. Patients received oral Dimebon, 20 mg three times a day (60 mg/day), or placebo. The primary efficacy endpoint was the ADAS-cog and the secondary efficacy endpoints were the CIBIC-plus, the MMSE, the ADCS-ADL and the NPI. Medivation is presently completing a 12-month extension of this trial and expects to report top-line data in the second quarter of 2007. Medivation also expects to enter global Phase 3 studies of Dimebon in Alzheimer's disease in 2008 and, assuming positive data, to submit marketing applications in the U.S. and Europe in 2010 for this indication.

About Dimebon

Dimebon, the Company's lead product candidate, is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's disease and Huntington's disease, making it a potential treatment for these and other neurodegenerative diseases. Based on the clinical and preclinical data generated to date, Medivation believes that Dimebon operates by a novel mechanism of action and may exert a neuroprotective effect in multiple areas of the central nervous system. Dimebon appears to block a new target that involves mitochondrial pores, which are believed to play a role in the cell death that is associated with neurodegenerative diseases and the aging process. Medivation is currently evaluating Dimebon in clinical trials in both Alzheimer's and Huntington's diseases.

Abo
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... HILLS, Calif. , July 30, 2015 /PRNewswire/ ... nanoparticle drug delivery platforms, has received Orphan Drug ... for a second drug product that uses NanoSmart,s ... a formulation of dactinomycin for the treatment of ... cancer. The FDA granted NanoSmart,s Orphan Drug Designation ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... provider of the award-winning PatientPad® self-service ... it has earned top honors in the "Emerging Technology ... presented by the Technology Association of Georgia (TAG) and ... this prestigious award for the PatientPad – an innovative ...
... Akron General Medical Center has joined managed technology ... communications capability and efficiency paired with major cost savings. ... with cost reductions both in short and long-term operating ... General,s strategic objectives in the coming years. ...
Cached Medicine Technology:Digital Assent Wins Back-to-Back Spirit of Endeavor Awards, This Year for Top "Emerging Technology Company" 2Digital Assent Wins Back-to-Back Spirit of Endeavor Awards, This Year for Top "Emerging Technology Company" 3Hosted Technology Exchange Welcomes Akron General 2
(Date:7/30/2015)... ... ... Ross A. Clevens, MD, FACS has been reappointed by the ... This is Dr. Clevens’ second appointment by the prestigious school. Over the ... presence and a valuable mentoring program for medical students. , The ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Mesothelioma Applied ... Mesothelioma Patient Registry Act of 2015’. The bill was introduced in Congress yesterday ... (R-NY), Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose ...
(Date:7/30/2015)... , ... July 30, 2015 , ... Using the latest ... and teach people more effective ways to prevent and manage major depression. , “Suicide ... fast enough, so people fall through the cracks and die needlessly everyday,” says Walker. ...
(Date:7/30/2015)... ... 2015 , ... Boston Web Marketing is proud ... Partners is the platform for search marketing agencies to communicate with the Google ... to run successful search marketing campaigns. Google Partners also affords businesses the opportunity ...
(Date:7/30/2015)... , ... July 30, 2015 , ... Between 2012 and ... the Health News Florida on June 17th. Those untreated heroin use disorders ... to prevent the spread of dirty needles throughout the community. Ultimately Florida’s HIV infection ...
Breaking Medicine News(10 mins):Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3
... (HealthDay News) -- Pregnant women should get a flu shot ... experts say. Pregnancy increases the risk of serious complications ... the March of Dimes. Not only does getting vaccinated ... also confer protection to the baby once it,s born, said ...
... the first time a particlular gene,s link to optimism, self-esteem and ... three critical psychological resources for coping well with stress and ... for a few years, and it is not the gene I ... UCLA and senior author of the new research. "I knew there ...
... , WEDNESDAY, Sept. 14 (HealthDay News) -- Residents of lower ... a new study finds. Sudden cardiac arrest is different ... stops beating and circulation of blood and oxygen to the ... moments. In the study, researchers from the United States ...
... The world,s health professions have launched an easy-to-use, practical ... professionals reduce the risk of noncommunicable diseases (NCDs) ... (1). The WHPA Health Improvement Card consists of a ... and health professionals. , This is part of efforts ...
... HealthDay Reporter , TUESDAY, Sept. 13 (HealthDay News) -- Preventing ... years is the goal of U.S. health officials, who launched ... aim is to raise awareness of the risk factors for ... the country; to improve access to good care; and to ...
... HealthDay Reporter , TUESDAY, Sept. 13 (HealthDay News) ... bicuspid aortic valve live in fear of sudden death, but ... life-threatening complication called aortic dissection. However, these people are ... aneurysm, or bulge in the wall of the aorta, researchers ...
Cached Medicine News:Health News:Pregnant Women Reminded to Get Flu Vaccine 2Health News:UCLA psychologists discover a gene's link to optimism, self-esteem 2Health News:UCLA psychologists discover a gene's link to optimism, self-esteem 3Health News:UCLA psychologists discover a gene's link to optimism, self-esteem 4Health News:Sudden Cardiac Arrest More Common in Poorer Neighborhoods 2Health News:Health professions launch Health Improvement Card to reduce NCD risk 2Health News:U.S. Seeks to Prevent 1 Million Heart Attacks, Strokes 2Health News:U.S. Seeks to Prevent 1 Million Heart Attacks, Strokes 3Health News:Heart Defect Seems to Pose Low Risk of Aorta Tear 2
Used with Temporary Myocardial Heartwires....
Implantable medical grade silicone end cap for insulation and sealing protection of 5 mm or 3.2 mm connectors....
... InSync ICD cardiac resynchronization and ICD device ... (BOL). The unit's RV only sensing provides ... and LV depolarizations, eliminating this cause of ... to LV separation for optimized hemodynamics. Proven ...
... The Guidant Contak Renewal 3 ... ventricular tachyarrhythmia therapy and cardiac ... right ventricular (RV) and left ... Designed to reduce irregular ventricular ...
Medicine Products: